{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:53:44Z","timestamp":1794718424834,"version":"4.9.1"},"reference-count":15,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP. In CP, the 8-year survival was \u2264 15% before 1983, 42%-65% from 1983-2000, and 87% since 2001. Survival was worse in older patients (P = .004), but this was less significant since 2001 (P = .07). Survival by Sokal risk was significantly different before 2001 (P &lt; .001), but not since 2001 (P = .4). In AP, survival improved over time (P &lt; .001); the 8-year survival in patients treated since 2001 was 75%. Survival by age was not different in years &lt; 2001 (P = .09), but was better since 2001 in patients \u2264 70 years of age (P = .004). In BP, the median survival improved over time (P &lt; .001), although it has been only 7 months since 2001. In summary, survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML. Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML.<\/jats:p>","DOI":"10.1182\/blood-2011-08-358135","type":"journal-article","created":{"date-parts":[[2012,1,7]],"date-time":"2012-01-07T06:06:15Z","timestamp":1325916375000},"page":"1981-1987","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":292,"title":["Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience"],"prefix":"10.1182","volume":"119","author":[{"given":"Hagop","family":"Kantarjian","sequence":"first","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quintas-Cardama","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Shan","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Rios","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"Cancer Center and Geriatric Center, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Departments of Leukemia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111808404020200_B1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111808404020200_B2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111808404020200_B3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111808404020200_B4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/cncr.11665","article-title":"Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon alpha regimens for early chronic phase.","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"2019111808404020200_B5","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/1097-0142(19871015)60:8<1708::AID-CNCR2820600803>3.0.CO;2-1","article-title":"Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron.","volume":"60","author":"Walters","year":"1987","journal-title":"Cancer"},{"issue":"7","key":"2019111808404020200_B6","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia.","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"issue":"4","key":"2019111808404020200_B7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"2019111808404020200_B8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia.","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"2019111808404020200_B9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as frontline treatment for patients with chronic myeloid leukemia in early chronic phase.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808404020200_B10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111808404020200_B11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1965","journal-title":"J Am Stat Assoc"},{"key":"2019111808404020200_B12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Cox Regression models and life tables.","volume":"34","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"4","key":"2019111808404020200_B13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"10","key":"2019111808404020200_B14","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.13045","article-title":"Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level.","volume":"93","author":"Brenner","year":"2008","journal-title":"Haematologica"},{"key":"2019111808404020200_B15","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"The success story of targeted therapy in chronic myeloid leukemia: a population based study of 3173 patients diagnosed in Sweden 1973-2008.","volume":"28","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/9\/1981\/1497871\/zh800912001981.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/9\/1981\/1497871\/zh800912001981.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:45:58Z","timestamp":1742312758000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/9\/1981\/30230\/Improved-survival-in-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-358135","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,1]]}}}